Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway
Abstract Background New acute and preventive migraine medications are available, but data on current treatment patterns are limited. This study describes migraine treatment patterns among patients initiating novel acute migraine specific medications (nAMSMs), overall and by prior use of anti-calcito...
Main Authors: | Zifan Zhou, Robert Urman, Karminder Gill, Andrew S. Park, Fiston Vuvu, Leah B. Patel, Jingsong Lu, Rolin L. Wade, Lindsay Frerichs, Mark E. Bensink |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-11-01
|
Series: | The Journal of Headache and Pain |
Subjects: | |
Online Access: | https://doi.org/10.1186/s10194-023-01678-y |
Similar Items
-
New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
by: Damiana Scuteri, et al.
Published: (2019-04-01) -
Blocking CGRP in migraine patients – a review of pros and cons
by: Marie Deen, et al.
Published: (2017-09-01) -
CGRP-targeted medication in chronic migraine - systematic review
by: Renato Oliveira, et al.
Published: (2024-04-01) -
Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor
by: Hans-Christoph Diener, et al.
Published: (2020-04-01) -
Calcitonin gene relating peptide inhibitors in combination for migraine treatment: A mini-review
by: Tulsi Shah, et al.
Published: (2023-03-01)